DB:3NQ

Stock Analysis Report

Executive Summary

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has NanoCarrier's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 3NQ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.7%

3NQ

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

-35.6%

3NQ

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: 3NQ underperformed the German Biotechs industry which returned 10% over the past year.

Return vs Market: 3NQ underperformed the German Market which returned 12.8% over the past year.


Shareholder returns

3NQIndustryMarket
7 Day-3.7%0.4%-0.9%
30 Day-6.4%-3.2%-0.4%
90 Day-20.8%4.6%2.3%
1 Year-35.6%-35.6%10.3%10.0%16.3%12.8%
3 Year-68.9%-68.9%49.4%47.8%15.8%5.7%
5 Year-77.1%-77.1%13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is NanoCarrier's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NanoCarrier undervalued compared to its fair value and its price relative to the market?

1.81x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 3NQ's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 3NQ's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 3NQ is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 3NQ is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 3NQ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 3NQ is good value based on its PB Ratio (1.8x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is NanoCarrier forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NanoCarrier has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has NanoCarrier performed over the past 5 years?

-15.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3NQ is currently unprofitable.

Growing Profit Margin: 3NQ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 3NQ is unprofitable, and losses have increased over the past 5 years at a rate of -15.1% per year.

Accelerating Growth: Unable to compare 3NQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 3NQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 3NQ has a negative Return on Equity (-15.69%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is NanoCarrier's financial position?


Financial Position Analysis

Short Term Liabilities: 3NQ's short term assets (¥8.2B) exceed its short term liabilities (¥149.0M).

Long Term Liabilities: 3NQ's short term assets (¥8.2B) exceed its long term liabilities (¥28.0M).


Debt to Equity History and Analysis

Debt Level: 3NQ is debt free.

Reducing Debt: 3NQ has no debt compared to 5 years ago when its debt to equity ratio was 3.9%.


Balance Sheet

Inventory Level: 3NQ has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 3NQ's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 3NQ has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 3NQ has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -16.1% each year


Next Steps

Dividend

What is NanoCarrier's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 3NQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 3NQ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 3NQ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 3NQ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 3NQ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

13.4yrs

Average board tenure


CEO

Tetsuhito Matsuyama 0

0.3yrs

Tenure

Mr. Tetsuhito Matsuyama is President & Director since November 2019 and had been the Chief Financial Officer and Head of Chief Executive Officer's Office at NanoCarrier Co., Ltd. since January 2015 until N ...


Board Members

NamePositionTenureCompensationOwnership
Hiroyuki Hanada
Chief Business Officer and Director11.7yrsno datano data
Ichiro Nakatomi
Director23.7yrsno data1.53% ¥2.2m
Teruo Okano
External Director23.7yrsno data0.48% ¥672.9k
Akira Ohashi
External Director16.7yrsno data0.028% ¥39.1k
Tadashi Morishima
External Auditor20.3yrsno data0.044% ¥61.9k
Toshio Furuta
External Auditor13.4yrsno datano data
Atsushi Matsumura
External Director7.9yrsno datano data
Tomoyuki Fujisawa
External Director5.7yrsno datano data
Manish Mishra
Director0.7yrsno data0.068% ¥96.1k
Mieko Nakayama
Audit & Supervisory Board Member0yrsno data0.00015% ¥211.5

13.4yrs

Average Tenure

63yo

Average Age

Experienced Board: 3NQ's board of directors are seasoned and experienced ( 13.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.5%.


Top Shareholders

Company Information

NanoCarrier Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NanoCarrier Co., Ltd.
  • Ticker: 3NQ
  • Exchange: DB
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥17.109b
  • Listing Market Cap: JP¥141.011m
  • Shares outstanding: 66.06m
  • Website: https://www.nanocarrier.co.jp

Number of Employees


Location

  • NanoCarrier Co., Ltd.
  • Chuou 144-15
  • 226-39 Wakashiba
  • Kashiwa
  • Chiba
  • 277-0871
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4571TSE (The Tokyo Stock Exchange)YesCommon SharesJPJPYMar 2008
3NQDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2008

Biography

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan. Its product pipeline includes NC-6004 Cisplatin micelle for the treatment of pancreatic, head and neck, non-small cell lung, bladder, and biliary track cancers; and VB-111, a non-replicating Adeno 5 vector for the treatment of rGBM/ovarian cancer, etc. The company’s product pipeline also comprise NC-6300 Epirubicin micelle for soft tissue sarcoma; NC-4016 Dach-platinum micelle for solid cancers; and NK105 Paclitaxel micella for the treatment of breast and gastric cancers. NanoCarrier Co., Ltd. was founded in 1996 and is headquartered in Kashiwa, Japan. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 21:33
End of Day Share Price2020/02/21 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.